comparemela.com

Latest Breaking News On - Jean marc steens - Page 1 : comparemela.com

ABIVAX: Abivax Presents First-half 2021 Financial Results and Operations Update

ABIVAX: Abivax Presents First-half 2021 Financial Results and Operations Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Abivax Presents First-half 2021 Financial Results and Operations Update

Abivax Presents First-half 2021 Financial Results and Operations Update
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Abivax presents first-half 2021 financial results and operations update

Abivax presents first-half 2021 financial results and operations update
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Abivax Appoints Dr Sophie Biguenet, M D , as Chief Medical Officer

Investegate |ABIVAX Announcements | ABIVAX: Abivax appoints Dr Sophie Biguenet, M D , as Chief Medical Officer

DGAP-News: ABIVAX / Key word(s): Personnel Abivax appoints Dr Sophie Biguenet, M.D., as Chief Medical Officer 01.03.2021 / 18:00 Abivax Chief Medical Officer Dr Sophie Biguenet joins Abivax on March 1 As CMO, Sophie Biguenet will drive Abivax s main clinical program of ABX464 for the treatment of inflammatory bowel diseases (IBD) into phase 3 testing in 2021 PARIS, March 1, 2021 - 06:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company modulating the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces the appointment of Dr Sophie Biguenet as Chief Medical Officer, effective on March 1, 2021, based in Paris. Dr Biguenet brings 25 years of experience in academia and in the biopharmaceutical industry with an extensive track record in international clinical development, leading to the successful registration of several new drug products across various treatment areas, inc

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.